Patent · US Active

EGFR inhibitors and methods of treating disorders

US9908884B2 · kind B2 · utility

10Cited by
68References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 5, 2010
Grant dateMar 6, 2018
Priority date
Expiry dateMay 5, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D403/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.